SEC Form 4 · accession 0001415889-15-001201
INNOVUS PHARMACEUTICALS, INC. · INNV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lynnette Dillen
Officer — EVP, CFO
Period of report
Mar 31, 2015
Accepted (ET)
Apr 1, 2015 · 6:18 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411879
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF4,F1,F2,F3 | — | Mar 31, 2015 | A | 2,570,000 | A | — | — | Common Stock | 2,570,000 | 2,570,000 | D |
Explanation of responses
- F1Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- F2The Reporting Person was granted a Restricted Stock Unit award on March 31, 2015 of 2,570,000 shares, of which 856,667 vested immediately and the remaining 1,713,333 shares will vest in equal installments on a monthly basis over the next twenty-four (24) months.
- F3These restricted stock units are scheduled to vest 100% on March 31, 2017.
- F4These restricted stock units were granted pursuant to the Issuer's 2014 Equity Incentive Plan.